Immune selection after antigen-specific immunotherapy of melanoma

Surgery

Volumn 126, Issue 2, 1999, Pages 112-120

  Riker, Adam ^a   Cormier, Janice ^a   Panelli, Monica ^a   Kammula, Udai ^a   Wang, Ena ^a   Abati, Andrea ^a   Fetsch, Patricia ^a   Lee, Kang Hun ^a   Steinberg, Seth ^a   Rosenberg, Steven ^a   Marincola, Francesco ^a,b  

^a Division of Clinical Sciences   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 100; HLA ANTIGEN; INTERLEUKIN 2; MELANOMA ANTIGEN; UNCLASSIFIED DRUG; VACCINE;

ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MELANOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; VACCINATION;

EID: 0032838613     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(99)70143-1     Document Type: Article

References (24)

1. 1. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N Engl J Med 1988;319:1676-80.
2. 2. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994;86:1159-66.
3. 3. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997;18:175-82.
4. 4. Boon T, Cottlie PG, Van deu Eynde B. Tumor antigens recognized by T cells. Immunol. Today 1997;18:267-8.
5. 5. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997;3:37-44.
6. 6. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with syn" thetic peptides. Cancer Res 1996;56:4749-57.
7. 7. Rosenberg SA, Yang JC, Schwartzentruber D, et al. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-7.
8. 8. Krausa P, Brywka M, Savage D, et al. Genetic polymorphism within HLA-A*02: significant alletic variation revealed in different populations. Tissue Antigens 1995;45:223-31.
9. 9. Player MA, Barracchini KC, Simonis TB, et al. Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocols. J Immunother Emphasis Tumor Immnnol 1996;19:357-63.
10. 10. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201 binding residues. J Immunol 1996;157:2539-48.
11. 11. Tsujisaki M, Sakaguchi K, Igarashi M, Richiardi P, Perosa F, Ferrone S. Fine specificity and idiotype diversity of the murine anti-HLA-A2, A28 monoclonal antibodies CR11-351 and KS1. Transplantation 1988;45:632-9.
12. 12. Marincola FM, Hijazi YM, Fetsch P, et al. Analysis of expression of the melanoma associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother 1996;19:192-205.
13. 13. Kawakami Y, Battles JK, Kobayashi T, et al. Production of recombinant MART-1 proteins and specific anti-MART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. J Immunol Methods 1997;202:13-25.
14. 14. Mantel N. Chi-square tests with one degree of freedom, extensions of the Mantel-Haenzel procedure. J Am Stat Assoc 1963;58:690-700.
15. 15. Cormier JN, Hijazi YM, Abati A, et al. Heterogeneous expression of melanoma-associated antigens (MAA) and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998;75:517-24.
16. 16. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487-94.
17. 17. Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997;18:89-95.
18. 18. Chen Y-T, Stockert E, Tsang S, Coplan KE, Old LJ. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci U S A 1995;92:8125-9.
19. 19. Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996;66:470-6.
20. 20. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-8.
21. 21. Lehmann F, Marchand M, Hainaut P, et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995;25:340-7.
22. 22. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. The loss of functional b2-microglobulin in metastatic melanomas from five patients undergoing immunotherapy. J Natl Cancer Inst 1996;88:100-8.
23. 23. Maeurer MJ, Gollin SM, Martin D, et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 1996;98:1633-41.
24. 24. Lee K-H, Panelli MC, Kim CJ, et al. Functional dissociation between local and systemic immune response following peptide vaccination. J Immunol 1998;161:4183-94.